Travere's FILSPARI gets standard EU marketing authorization; receives $17.5M milestone

Travere Therapeutics, Inc.

European Commission converts conditional approval to standard MA for FILSPARI (sparsentan) for primary IgAN in all EU member states, plus Iceland, Liechtenstein, Norway.
UK MHRA also converted to standard approval on April 15, 2025.
Company receives $17.5M milestone payment from CSL Vifor; eligible for additional market access and sales-based milestones.
Approval based on Phase 3 PROTECT Study showing significant slowing of kidney function decline vs. irbesartan.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.